Atlas Trials

Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

Clinical trial NCT07706933 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07706933
Sponsor
Henan Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Breast Cancer
Start date
2026-08-01
Primary completion
2028-06-30
Enrollment
456

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.